medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Number 06

<< Back Next >>

Ginecol Obstet Mex 2021; 89 (06)

Use of hormone replacement therapy in climacteric and gynecological cancer risk. Narrative review

Arteaga-Gómez AC, Zapata-Caballero CA, Arellano-Eguiluz A, Santoyo-Rosas SE, Robellada-Zárate CM

Language: Spanish
References: 40
Page: 464-471
PDF size: 213.16 Kb.


ABSTRACT

Objective: To identify and update, through a literature review, the magnitude of the risk involved in hormone replacement therapy in the incidence and recurrence of breast, ovarian, endometrial and cervical cancer in climacteric women. In addition, to evaluate the relationship with the time and type of treatment indicated.
Materials and Methods: Retrospective study, literature search of studies published from 2010 to 2020 with oncologic outcomes associated with hormone replacement therapy. The search was conducted in PubMed and Google Scholar search engines.
Results: We found 5848 related articles and discarded 3828 because they were published before 2010. The abstracts of 2020 articles were reviewed and 1980 were eliminated for not meeting the inclusion criteria. The final review was performed with 40 articles.
Conclusions: Based on what has been published, the evidence suggests that there is an increased risk of breast cancer in users of combined hormone replacement therapy; the greatest secondary risk is with progestins. For endometrial the risk is higher with estrogens alone. For ovarian cancer the evidence is not sufficient to guide practice. For cervical cancer, the evidence suggests that hormone therapy has no risk. The risks and benefits of hormone replacement therapy have considerable variations depending on the specific regimen and the individual circumstances of each patient.


REFERENCES

  1. Del Carmen MG, Rice LW. Management of menopausal symptoms in women with gynecologic cancers. Gynecol Oncol 2017; 146 (2): 427-35. https://doi.org/10.1016/j. ygyno.2017.06.013.

  2. Fait T. Menopause hormone therapy: latest developments and clinical practice. Drugs Context. 2019; 8: 212551. 10.7573/dic.212551. http://www.scielo.edu.uy/scielo. php?pid=S1688-12492011000300003&script=sci_arttext

  3. Khadilkar S. Menopausal Hormone Therapy: An Update. Endocrinology in Obstetrics and Gynecology. 2012; 396. doi: 10.1007/s13224-012-0269-y.

  4. Shifren JL, Crandall CJ, Manson JE. Menopausal Hormone Therapy. JAMA. 2019; 321 (24): 2458-9. doi:10.1001/ jama.2019.5346.

  5. Pirhadi R, Sinai Talaulikar V, Onwude J, Manyonda I. It is all in the name: The importance of correct terminology in hormone replacement therapy. Post Reprod Health. 2020 May 9. https://doi.org/10.1177/2053369120924175.

  6. Cagnacci A, Venier M. The Controversial History of Hormone Replacement Therapy. Medicina 2019; 55 (9). doi: 10.3390/medicina55090602.

  7. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019; 394 (10204):1159-68. https://doi.org/10.1016/S0140- 6736(19)31709-X.

  8. Angahar LT. An overview of breast cancer epidemiology, risk factors, pathophysiology, and cancer risks reduction. MOJ Biol Med 2017; 1 (4): 92-96. 10.15406/mojbm. 2017.01.00019.

  9. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors. Review of the Literature. Pathology & Oncology Research 2020; 26: 63. doi: 10.1007/s12253- 018-00569-x.

  10. Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of Menopausal Hormone Therapy with Breast Cancer Incidence and mortality during Long-term Follow-up of the WHI Randomized Clinical Trials. JAMA. 2020; 324 (4): 369-80. doi: 10.1001/jama.2020.9482.

  11. Beral V, Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362 (9382): 419-27. doi: 10.1016/ s0140-6736(03)14065-2.

  12. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24 (7): 728-53. doi: 10.1097/ GME.0000000000000921.

  13. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the WHI Randomized Trials. Obstetrical & Gynecological Survey 2014; 69: 83-5. doi: 10.1001/jama.2013.278040.

  14. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103-11. https:// doi.org/10.1007/s10549-007-9523-x.

  15. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer -is it safe?), a randomised comparison: trial stopped. Lancet. 2004 Feb 7;363(9407):453-5. https://doi.org/10.1016/S0140-6736(04)15493-7.

  16. Fahlén M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz, E. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. European Journal of Cancer 2013; 49 (1): 52-59. https://doi.org/10.1016/j.ejca.2012.07.003

  17. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008; 100 (7): 475-82. https:// doi.org/10.1093/jnci/djn058.

  18. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The WHI Randomized Trials. JAMA 2017; 318 (10): 927-38. doi: 10.1001/jama.2017.11217.

  19. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013; 34 (1): 130-62. https://doi. org/10.1210/er.2012-1043

  20. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85 (2): 304-13. https://doi.org/10.1016/0029-7844(94)00383-O.

  21. Bjarnason NH. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365 (9470): 1543-51. https://doi.org/10.1016/S0140- 6736(05)66901-2

  22. The North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement. Menopause. 2020 Sep;27(9):976–92. doi: 10.1097/ GME.0000000000001609

  23. Kingsberg S, Larkin L. Shining the light on genitourinary syndrome of menopause in survivors of breast cancer. Menopause 2017; 24: 1336-7. doi: 10.1097/ GME.0000000000001007.

  24. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol. 2005; 105 (4): 779- 87. doi: 10.1097/01.AOG.0000157116.23249.52

  25. Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas. 2016; 91: 25-35. https://doi. org/10.1016/j.maturitas.2016.05.013.

  26. Burness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012; (8): CD000402. https://doi.org/10.1002/14651858. CD000402.pub2.

  27. Fournier A, Dossus L, Mesrine S, Vilier A, Boutron-Ruault M-C, Clavel-Chapelon F, et al. Risks of endometrial cancer associated with different hormone Replacement Therapies in the E3N Cohort, 1992–2008. Am J Epidemiol 2014; 180 (5): 508-17. https://doi.org/10.1093/aje/kwu146.

  28. Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. Climacteric. 2016; 19 (4): 316-28. https://doi.org/10.108 0/13697137.2016.1187123.

  29. Arteaga-Gómez AC, Castellanos-Barroso G, Colin-Valenzuela A, García-Vargas J, Márquez-Acosta G, Reyes-Muñoz E. Efecto de la terapia hormonal en mujeres posmenopáusicas con antecedente de cáncer de endometrio. Ginecol Obstet Mex 2011; 79 (1): 11-7. http://www.scielo.edu.uy/ scielo.php?pid=S1688-12492011000300003&script=sci_ arttext

  30. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev 2018; 15: 5: CD008830. https://doi.org/10.1002/14651858.CD008830.pub3.

  31. Cho HW, Ouh YT, Lee JK, Hong JH. Effects of hormone therapy on recurrence in endometrial cancer survivors. J Gynecol Oncol 2019; 30 (4): e51. doi: 10.3802/jgo.2019.30.e51.

  32. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017; 14 (1): 9-32. doi. 10.20892/j.issn.2095-3941.2016.0084.

  33. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019; 393 (10177): 1240-53. https://doi. org/10.1016/S0140-6736(18)32552-2.

  34. D’Alonzo M, Bounous VE, Villa M, Biglia N. Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy. Medicine 2019; 55 (9). doi. 10.3390/ medicina55090573.

  35. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015; 385 (9980): 1835-42. https://doi. org/10.1016/S0140-6736(14)61687-1.

  36. Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database of Systematic Reviews. 2020. https://doi. org/10.1002/14651858.CD012559.pub2.

  37. Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016; 23 (3): 335-42. doi: 10.1097/ GME.0000000000000508.

  38. Roura E, Travier N, Waterboer T, de Sanjosé S, Bosch FX, Pawlita M, et al. The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One 2016; 11 (1): e0147029. https://doi.org/10.1371/journal.pone.0147029.

  39. Lumsden MA, Davies M, Sarri G, Diagnosis and Management of Menopause: NICE Guideline. JAMA Intern Med. 2016; 176 (8): 1205-6. doi: 10.1001/jamainternmed. 2016.2761.

  40. Angioli R, Luvero D, Armento G, Capriglione S, Plotti F, Scaletta G, et al. Hormone replacement therapy in cancer survivors: Utopia? Crit Rev Oncol Hematol 2018; 124: 51-60. https://doi.org/10.1016/j.critrevonc. 2018.02.005.




2020     |     www.medigraphic.com